Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
SUNNYVALE, Calif., Jan. 20, 2026 /PRNewswire/ -- Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast and accurate detection of ...
QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
Cepheid has received clearance from the US Food and Drug Administration (FDA) for its Xpert GI Panel, a multiplex polymerase chain reaction (PCR) gastrointestinal (GI) pathogen testing solution. The ...
Panel delivers rapid detection of five common bacterial pathogens for outpatient use, aiding fast and informed treatment decisions QIAGEN building momentum in the U.S. syndromic testing market with ...
“Infectious diseases don’t respect borders,” says Khoa Thai, a clinical microbiologist at the Star-shl medical diagnostics laboratory in the Netherlands. To limit their spread, we need a globally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results